Stockholm, Sweden – Barnik Invest Group today announced the acquisition of Idogen AB’s technology platform. This strategic move positions Barnik Invest to lead the development of innovative therapies based on antigen-specific dendritic cell-mediated tolerance.
The acquired technology platform holds immense potential to treat autoimmune diseases by modulating the immune system to target specific antigens. By harnessing the power of dendritic cells, this approach aims to restore immune tolerance and alleviate symptoms for patients suffering from debilitating conditions.
“We are excited to acquire this groundbreaking technology platform from Idogen AB,” said Hamid Bakhshi, CEO of Barnik Invest Group. “This acquisition aligns with our commitment to investing in innovative life science technologies and driving the development of transformative therapies. We believe this technology has the potential to revolutionize the treatment of autoimmune diseases and improve the lives of countless patients. ”A new company will be formed to focus on advancing the clinical development of this promising technology.
For more information, please contact;
Hamid Bakhshi, CEO
Telephone: +46738531165
E-mail: hamid.bakhshi@barnikinvest.com
About Barnik Invest Group
Barnik Invest Group is a leading 360 solution partner for small Life Science companies in the Nordics. The company provides a comprehensive suite of services to support its portfolio companies, including capital, clinical development, expertise, and commercialization. Through its fully-owned subsidiaries, Medicorent and StartUpPharma, Barnik Invest offers CRO services, outsourcing, recruitment, distribution, product development and commercialization solutions. Barnik’s mission is to nurture promising life science companies from early clinical development phase to commercialization, enabling them to achieve positive cash flows or successful exits and ultimately enhancing patient well-being and improving human health worldwide. For more information visit www.barnikinvest.com.
